

WHAT IS CLAIMED IS:

- 1 1. A method for controlling chronic inflammation in an individual, comprising:
2 administering to said individual an effective dosage of a pharmaceutical composition selected
3 from the group consisting of YG-Product, YGG-Product, Purified Leukocyte Dialysate Subfraction,
4 and a combination thereof.

- 1 2. The method of claim 1, wherein the chronic inflammation is evidenced by at least one
2 of elevated C-Reactive Protein and elevated serum fibrinogen.

- 1 3. The method of claim 1, wherein the chronic inflammation is evidenced by at least
2 one of elevated platelet count and elevated platelet activity due to the chronic inflammation.

- 1 4. The method of claim 1, wherein the individual has at least one condition selected
2 from the group consisting of hypertension, hypercholesterolemia, hypertriglyceridemia, and
3 obesity.

- 1 5. The method of claim 1, wherein the individual has at least one component of the
2 Metabolic Syndrome.

- 1 6. The method of claim 5, wherein the component of the Metabolic syndrome is selected
2 from the group consisting of obesity, insulin resistance, hypertension, dyslipidemia, , impaired
3 glucose tolerance, , accompanied by increased acute phase proteins including C-Reactive Protein
4 and fibrinogen.

1 7. The method of claim 1, wherein said individual has diabetes mellitus, coronary artery
2 disease or cancer.

1 8. A method for controlling elevated blood glucose level in an individual with
2 inflammation-related metabolic disturbances, comprising:

3 administering to said individual an effective dosage of a composition selected from the group
4 consisting of YG-Product, YGG-Product, Purified Leukocyte Dialysate Subfraction, or a
5 combination thereof.

1 9. The method of claim 8, wherein the individual has at least one component of the
2 Metabolic Syndrome.

1 10. A method for preventing chronic inflammation due to the presence of or potential
2 exposure to a pathogen, environmental particulates, or environmental toxins, said method
3 comprising:

4 administering to said individual an effective dosage of a pharmaceutical composition selected
5 from the group consisting of YG-Product, YGG-Product, Purified Leukocyte Dialysate Subfraction,
6 and a combination thereof.

1 11. A method for mitigating a symptom in a patient, said symptom characteristic of
2 chronic inflammation, said patient presenting said symptom, said method comprising administering
3 to the patient a pharmaceutical preparation containing an effective dosage amount of YG-Product,
4 YGG-Product, Purified Leukocyte Dialysate Subfraction, or a combination thereof.

1 12. The method of claim 11, wherein said patient has at least one component of the
2 Metabolic Syndrome.

1 13. The method of claim 12, wherein said symptom is at least one selected from the
2 group consisting of elevated blood pressure, atherogenic dyslipidemia, abdominal obesity, insulin
3 resistance with or without glucose intolerance, a proinflammatory state, and a prothrombotic state.

1 14. A method for mitigating a symptom in a patient, said symptom characteristic of an
2 inflammation-related metabolic disturbance, said patient presenting said symptom, said method
3 comprising administering to the patient a pharmaceutical preparation containing an effective dosage
4 amount of YG-Product, YGG-Product, Purified Leukocyte Dialysate Subfraction, or a combination
5 thereof.

1 15. The method of claim 14, wherein said patient has at least one component of the
2 Metabolic Syndrome.

1 16. The method of claim 15, wherein said component is at least one selected from the
2 group consisting of elevated blood pressure, atherogenic dyslipidemia, abdominal obesity, insulin
3 resistance with or without glucose intolerance, a proinflammatory state, and a prothrombotic state.

1 17. A method for deferring the progression of a patient from the Metabolic
2 Syndrome including Hypertension, to Diabetes Mellitus, Coronary Heart Disease, or Cancer, said
3 method comprising administering to the patient a pharmaceutical preparation containing an effective

4 dosage amount of YG-Product, YGG-Product, Purified Leukocyte Dialysate Subfraction, or a
5 combination thereof.

1 18. A method for preventing or mitigating development of inflammation-related sequelae
2 of exposure of a person to liquids or vapors containing organic solvents or hydrocarbon fuels, or to
3 environmental toxins capable of provoking chronic inflammation, said method comprising:

4 (a) administering to the person a pharmaceutical preparation containing an effective
5 dosage amount of YG-Product, YGG-Product, Purified Leukocyte Dialysate Subfraction, or a
6 combination thereof;

7 (b) monitoring the person for immune function response, inflammation, and blood
8 glucose level; and

9 (c) continuing to administer to the patient said pharmaceutical preparation until the
10 person shows a normal immune function response and normal measures of inflammatory parameters.

11